查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1464919

樹突細胞癌疫苗市場：依癌症類型、最終用途分類 - 2024-2030 年全球預測

Dendritic Cell Cancer Vaccine Market by Cancer Type (Breast Cancer, Liver Cancer, Lung Cancer), End-use (Hospitals, Research Institutes, Specialty Clinics) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

樹突細胞癌疫苗市場規模預計2023年為3.5006億美元，2024年達到3.9259億美元，預計2030年將達到8.2649億美元，複合年成長率為13.05%。

樹突細胞癌症疫苗利用樹突細胞誘發針對癌症的免疫反應。樹突細胞疫苗是免疫療法的一種形式，旨在教導免疫系統更有效地識別和攻擊癌細胞。樹突細胞癌疫苗主要應用於多種癌症的治療和管理，包括前列腺癌、黑色素瘤和白血病。公營和私營部門對研發活動的資金增加正在擴大對樹突狀細胞癌疫苗的需求。全球癌症負擔日益增加，需要先進的治療方法和樹突細胞疫苗。樹突狀細胞疫苗的開發和生產相關的高成本阻礙了市場成長。針對個別癌症特徵和免疫系統的疫苗開發的進步和功效的提高預計將為市場成長創造機會。擴大使用樹突細胞疫苗與其他癌症治療相結合以改善患者預後的研究活動預計將擴大市場範圍。

主要市場統計
基準年[2023] 35006萬美元
預測年份 [2024] 3.9259 億美元
預測年份 [2030] 8.2649億美元
複合年成長率（%） 13.05%

癌症類型：特異性針對癌細胞的前列腺癌樹突狀細胞癌疫苗增加了可能性

乳癌是世界上最常見的癌症之一，對創新治療方案的需求很大。樹突細胞疫苗因其提供標靶免疫療法、降低復發率和提高長期存活率的潛力而受到關注。由於其侵襲性和肝臟在藥物代謝中的作用，肝癌提出了獨特的挑戰。樹突細胞疫苗因其能夠特異性靶向癌細胞並刺激強大的免疫反應而無明顯毒性而特別有價值。肺癌死亡率很高，需要創新的治療方法。樹突細胞疫苗為個別患者提供了一種非侵入性的選擇，並有可能改變肺癌治療的模式。卵巢癌通常在晚期才被診斷出來，因此創新的治療方法非常重要。樹突狀細胞疫苗因其在誘導針對卵巢癌特異性腫瘤抗原的強烈免疫反應方面的作用而引人注目。胰臟癌的性質和不良預後增加了對樹突狀細胞疫苗等創新治療方法的需求，這為透過個人化免疫療法改善存活率帶來了希望。前列腺癌是男性最常見的癌症之一，增加了對特異性針對癌細胞而不影響正常組織的治療方法的需求。樹突細胞疫苗是一個快速發展的領域，具有持久緩解和減少副作用的潛力。

最終用途：在綜合護理設施醫院增加樹突狀細胞癌疫苗的使用。

醫院是樹突細胞癌疫苗的重要最終使用部分，因為它們是包括癌症患者的診斷、治療和追蹤的綜合護理設施。大型醫院，尤其是腫瘤專科醫院，將是管理這些疫苗的關鍵。醫院的需求是由對綜合醫療服務和針對腫瘤的多學科團隊提供個人化護理的需求所推動的。研究機構對於樹突狀細胞癌疫苗的開發和進步至關重要。這些研究機構經常與生物技術公司合作，推動疫苗開發和臨床試驗的前沿。研究機構因其有能力進行深入研究、重要臨床試驗和開發下一代癌症疫苗而受到青睞。專科診所為樹突狀細胞癌疫苗的接種提供了更集中和專業的環境，專門針對特定的癌症患者。這些診所與研究機構和醫院密切合作，確保患者接受最新的治療，並提供適合每位患者的治療方案。專科診所以患者為中心，提供量身定做的治療計劃和後續護理。

區域洞察

在美洲，人們非常關注技術創新和癌症疫苗的開發。美洲持有多項與樹突細胞癌疫苗相關的專利，凸顯其在研發方面的主導地位。美國國立衛生美國(NIH) 等政府機構和私人企業的資助和投資十分活躍，並正在促進高級臨床試驗。歐盟在「地平線歐洲」等計畫下促進成員國之間的重要研究措施和合作。這種合作促進了專利申請和創新治療方法的引入。歐洲藥品管理局 (EMA) 在核准和監管樹突狀細胞癌疫苗、確保其安全性和有效性方面發揮關鍵作用。在中東和非洲地區，人們對包括樹突細胞疫苗在內的先進癌症治療方法越來越感興趣。亞太地區樹突狀細胞癌疫苗市場顯示出巨大的成長潛力。由於政府對生物技術研究的大力支持、有利的監管政策和大量投資，包括中國和日本在內的國家處於領先地位。日本憑藉其先進的醫療保健系統和研究能力，不斷為創新癌症治療方法的發展做出貢獻。

FPNV定位矩陣

FPNV定位矩陣對於評估樹突狀細胞癌疫苗市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對樹突狀細胞癌疫苗市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭評估及資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行綜合評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.樹突細胞癌疫苗市場規模及預測為何？

2.在樹突細胞癌疫苗市場預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.樹突細胞癌疫苗市場的技術趨勢和法規結構是什麼？

4.樹突狀細胞癌疫苗市場主要廠商的市場佔有率是多少？

5.進入樹突狀細胞癌疫苗市場的合適形式和策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球癌症發生率增加
      • 免疫療法和個人化醫療的持續進步
    • 抑制因素
      • 樹突細胞疫苗技術開發成本高
    • 機會
      • 加大樹突細胞生物學和疫苗技術領域的研發力度
      • 加速癌症治療開發的支持性法規結構
    • 任務
      • 對樹突細胞疫苗技術的好處認知不足
  • 市場區隔分析
    • 癌症類型：可特異性靶向癌細胞的前列腺癌樹突狀細胞癌疫苗的潛力不斷成長
    • 最終用途：在醫院綜合護理設施中增加樹突狀細胞癌疫苗的使用
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章樹突細胞癌疫苗市場：依癌症類型

  • 乳癌
  • 肝癌
  • 肺癌
  • 卵巢癌
  • 胰臟癌
  • 攝護腺癌

第7章樹突細胞癌疫苗市場：依最終用途分類

  • 醫院
  • 調查機構
  • 專科診所

第8章美洲樹突細胞癌疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區樹突細胞癌疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲樹突細胞癌疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 市場佔有率分析（2023）
  • FPNV定位矩陣（2023）
  • 競爭情境分析
    • BioNTech 開始基於 mRNA 的個人化新抗原特異性免疫療法的 2 期試驗，擴大後期臨床腫瘤學產品組合
  • 戰略分析和建議

第12章競爭組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-351BAD503B28

[194 Pages Report] The Dendritic Cell Cancer Vaccine Market size was estimated at USD 350.06 million in 2023 and expected to reach USD 392.59 million in 2024, at a CAGR 13.05% to reach USD 826.49 million by 2030.

The dendritic cell cancer vaccine utilizes dendritic cells to induce an immune response against cancer. Dendritic cell vaccines are a form of immunotherapy that aims to teach the immune system to recognize and attack cancer cells more effectively. Dendritic cell cancer vaccines find their primary application in the treatment and management of several cancers, such as prostate cancer, melanoma, and leukemia. Rising funding in research and development activities from both public and private sectors is expanding the need for dendritic cell cancer vaccines. The growing global cancer burden globally necessitates advanced therapies and dendritic cell vaccines. The high associated with the development and production of dendritic cell vaccines hamper the market growth. The growing development of vaccines tailored to the individual's cancer profile and immune system for enhanced effectiveness is expected to create opportunities for market growth. Expanding research activities that combine the use of dendritic cell vaccines with other cancer treatments to improve patient outcomes are expected to expand the scope of the market.

KEY MARKET STATISTICS
Base Year [2023] USD 350.06 million
Estimated Year [2024] USD 392.59 million
Forecast Year [2030] USD 826.49 million
CAGR (%) 13.05%

Cancer Type: Rising potential of dendritic cell cancer vaccine for prostate cancer that can specifically target cancer cells

With breast cancer being one of the most common cancers worldwide, there is a significant demand for innovative treatment options. Dendritic cell vaccines are sought after for their potential to offer targeted immunotherapy, reduce recurrence rates, and improve long-term survival. Liver cancer presents unique challenges due to its aggressive nature and the liver's role in drug metabolism. Dendritic cell vaccines are particularly valuable for their ability to specifically target cancer cells and stimulate a robust immune response without significant toxicity. Lung cancer's high mortality rate necessitates innovative treatment approaches. Dendritic cell vaccines offer a non-invasive option that can be tailored to individual patients, potentially transforming lung cancer treatment paradigms. Ovarian cancer is often diagnosed at a late stage, making innovative treatments critical. Dendritic cell vaccines are appealing due to their role in eliciting a strong immune response against tumor antigens specific to ovarian cancer. The nature and poor prognosis associated with pancreatic cancer heighten the need for innovative therapies, inclduing dendritic cell vaccines, which offer hope for improving survival rates through personalized immunotherapy. Prostate cancer is one of the most prevalent cancers in men, with a growing need for treatments that can specifically target cancer cells without affecting normal tissue. Dendritic cell vaccines represent a burgeoning field offering the potential for sustained remission and fewer side effects.

End-use: Rising usage of dendritic cell cancer vaccine across hospitals due to their comprehensive care facilities

Hospitals represent a crucial end-use segment for dendritic cell cancer vaccines due to their comprehensive care facilities, including diagnosis, treatment, and follow-up for cancer patients. Larger hospitals, particularly those with specialized oncology departments, are key to administering these vaccines. The need in hospitals is driven by the requirement for integrative healthcare services and multidisciplinary teams specializing in oncology to provide personalized medicine. Research institutes are pivotal in the development and advancement of dendritic cell cancer vaccines. These institutes often partner with biotechnological companies to push the frontiers of vaccine development and clinical trials. The preference for research institutes emanates from their capability to conduct in-depth studies, critical trials, and development of next-generation cancer vaccines. Specialty clinics offer a more focused and specialized setting for the administration of dendritic cell cancer vaccines, catering specifically to patients with certain types of cancers. These clinics provide personalized care, often collaborating closely with both research organizations and hospitals to ensure the latest treatments are available. Specialty clinics are favored for their patient-centric approach, offering tailored treatment plans and follow-up care.

Regional Insights

In the Americas, there is a strong emphasis on innovation and the development of cancer vaccines. The Americas holds numerous patents related to dendritic cell cancer vaccines, underscoring its leading position in research and development. Funding and investments from both governmental bodies, such as the National Institutes of Health (NIH) and private entities, are robust, facilitating advanced clinical trials. The EU promotes significant research initiatives and collaborations across member states under programs including, Horizon Europe. Such cooperation enhances patent filings and the introduction of innovative therapies. The European Medicines Agency (EMA) plays a crucial role in the approval and regulation of dendritic cell cancer vaccines, ensuring their safety and efficacy. The Middle East & Africa region exhibit growing interest in advanced cancer treatments, including dendritic cell vaccines. Asia-Pacific region demonstrates significant potential for growth in the dendritic cell cancer vaccine market. Countries including China and Japan are at the forefront, driven by strong governmental support for biotechnology research, favorable regulatory policies, and substantial investments. Japan, with its advanced healthcare system and research capabilities, continues to contribute to the development of innovative cancer treatments.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Dendritic Cell Cancer Vaccine Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Dendritic Cell Cancer Vaccine Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Dendritic Cell Cancer Vaccine Market, highlighting leading vendors and their innovative profiles. These include Aduro Biotech, APAC Biotech, Argos Therapeutics, Batavia Biosciences B.V., Creative Biolabs, Dendreon Pharmaceuticals, GSK PLC, ImmunoCellular Therapeutics, JW CreaGene, Northwest Biotherapeutics, Northwest Biotherapeutics, Inc., and Nouscom.

Market Segmentation & Coverage

This research report categorizes the Dendritic Cell Cancer Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Cancer Type
    • Breast Cancer
    • Liver Cancer
    • Lung Cancer
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
  • End-use
    • Hospitals
    • Research Institutes
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Dendritic Cell Cancer Vaccine Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Dendritic Cell Cancer Vaccine Market?

3. What are the technology trends and regulatory frameworks in the Dendritic Cell Cancer Vaccine Market?

4. What is the market share of the leading vendors in the Dendritic Cell Cancer Vaccine Market?

5. Which modes and strategic moves are suitable for entering the Dendritic Cell Cancer Vaccine Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer cases worldwide
      • 5.1.1.2. Continuous advancements in immunotherapy and personalized medicines
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of development of dendritic cell vaccine technology
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising research and development efforts in the field of dendritic cell biology and vaccine technology
      • 5.1.3.2. Supportive regulatory frameworks for accelerating the development of cancer therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness associated with benefits of dendritic cell vaccine technology
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Cancer Type: Rising potential of dendritic cell cancer vaccine for prostate cancer that can specifically target cancer cells
    • 5.2.2. End-use: Rising usage of dendritic cell cancer vaccine across hospitals due to their comprehensive care facilities
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Dendritic Cell Cancer Vaccine Market, by Cancer Type

  • 6.1. Introduction
  • 6.2. Breast Cancer
  • 6.3. Liver Cancer
  • 6.4. Lung Cancer
  • 6.5. Ovarian Cancer
  • 6.6. Pancreatic Cancer
  • 6.7. Prostate Cancer

7. Dendritic Cell Cancer Vaccine Market, by End-use

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Research Institutes
  • 7.4. Specialty Clinics

8. Americas Dendritic Cell Cancer Vaccine Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Dendritic Cell Cancer Vaccine Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Dendritic Cell Cancer Vaccine Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy
  • 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. DENDRITIC CELL CANCER VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. DENDRITIC CELL CANCER VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. DENDRITIC CELL CANCER VACCINE MARKET DYNAMICS
  • FIGURE 7. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. DENDRITIC CELL CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. DENDRITIC CELL CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DENDRITIC CELL CANCER VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LIVER CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 30. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 35. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 36. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 37. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 38. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 39. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 40. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 41. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 42. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 43. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 46. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 47. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 48. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 49. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 50. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 51. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 54. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 55. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 56. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 66. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 67. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 70. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 71. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 74. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 75. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 78. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 79. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 82. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 83. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 86. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 90. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 91. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 94. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 98. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 99. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 102. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 103. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 106. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 107. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 110. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 117. DENMARK DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. DENMARK DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. DENMARK DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 120. DENMARK DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 121. EGYPT DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. EGYPT DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. EGYPT DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 124. EGYPT DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 125. FINLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. FINLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. FINLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 128. FINLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 129. FRANCE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. FRANCE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. FRANCE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 132. FRANCE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 133. GERMANY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. GERMANY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. GERMANY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 136. GERMANY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 137. ISRAEL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. ISRAEL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. ISRAEL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 140. ISRAEL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 141. ITALY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. ITALY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. ITALY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 144. ITALY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. NETHERLANDS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. NETHERLANDS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 148. NETHERLANDS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 149. NIGERIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. NIGERIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. NIGERIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 152. NIGERIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 153. NORWAY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. NORWAY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. NORWAY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 156. NORWAY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 157. POLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. POLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. POLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 160. POLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 161. QATAR DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. QATAR DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. QATAR DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 164. QATAR DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 165. RUSSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. RUSSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. RUSSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 168. RUSSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. SAUDI ARABIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. SAUDI ARABIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 172. SAUDI ARABIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. SOUTH AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 176. SOUTH AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 177. SPAIN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. SPAIN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. SPAIN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 180. SPAIN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 181. SWEDEN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. SWEDEN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. SWEDEN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 184. SWEDEN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. SWITZERLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. SWITZERLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 188. SWITZERLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 189. TURKEY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. TURKEY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. TURKEY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 192. TURKEY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. UNITED ARAB EMIRATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. UNITED ARAB EMIRATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 196. UNITED ARAB EMIRATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. UNITED KINGDOM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. UNITED KINGDOM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 200. UNITED KINGDOM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 201. DENDRITIC CELL CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 202. DENDRITIC CELL CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2023